Progress in nano-drug delivery of artemisinin and its derivatives: towards to use in immunomodulatory approaches
Source abstract
Abstract
In recent years, artemisinin (ART) and its derivatives have highlighted according to their effects on highly aggressive cancers, as well as treatment of malaria and leishmaniasis, besides presenting anti-inflammatory and antibacterial activity. It has also been shown that ART compounds have the ability to modulate the immune response by regulating cell proliferation and cytokine release. These effects may be beneficial and improve the treatment of cancer and parasitic diseases by increasing therapeutic success, but it has some pharmacological limitations such as low bioavailability, short half-life and limited tissue access. Nanotechnology has been explored during the last decades, notably in the design of drug carrier systems which includes polymeric, lipid and inorganic nanoparticles, cyclodextrins inclusion complexes, liposomes, carbon nanotubes, among others. These nanostructured drug delivery systems bring benefits both increased therapeutic efficacy and reduced toxicity. This review article aims to give an overview of the current progress in nanostructured drug carriers used for encapsulation of ART and its derivatives yielding examples of successful outcomes. The data collection suggests future applications of ART and derivatives encapsulated in nano delivery systems in clinical trials and prospects for use of ART loaded nanosystems in immunomodulatory responses.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Monoclonal and Polyclonal Antibodies Research · Computational Drug Discovery Methods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Immunology, Brasil University (UnBR)
Institute of Science and Technology of Sorocaba, São Paulo State University
Faculty of Medicine São Leopoldo Mandic
References (56)
Show source-provided references
1. 10.1016/j.biotechadv.2015.08.00110.1016/j.biotechadv.2015.08.001 ↗
2. 10.1002/ptr.75810.1002/ptr.758 ↗
3. 10.1055/s-2002-3257010.1055/s-2002-32570 ↗
4. 10.1186/1472-6882-14-26610.1186/1472-6882-14-266 ↗
5. 10.1055/s-0042-10874010.1055/s-0042-108740 ↗
6. 10.12988/asb.2014.452510.12988/asb.2014.4525 ↗
7. 10.1016/j.jep.2012.03.02410.1016/j.jep.2012.03.024 ↗
8. 10.1136/jclinpath-2016-20372110.1136/jclinpath-2016-203721 ↗
9. 10.1016/j.cell.2016.11.01010.1016/j.cell.2016.11.010 ↗
10. 10.1016/0378-5173(91)90213-810.1016/0378-5173(91)90213-8 ↗
11. 10.3390/molecules2202032310.3390/molecules22020323 ↗
12. 10.1016/j.pharmthera.2016.07.00210.1016/j.pharmthera.2016.07.002 ↗
13. 10.1016/j.ejphar.2011.06.04410.1016/j.ejphar.2011.06.044 ↗
14. 10.1155/2015/43571310.1155/2015/435713 ↗
15. 10.1016/B978-0-323-52725-5.00012-510.1016/B978-0-323-52725-5.00012-5 ↗
16. 10.1016/j.jconrel.2015.09.06210.1016/j.jconrel.2015.09.062 ↗
17. 10.1016/j.colsurfb.2014.12.04110.1016/j.colsurfb.2014.12.041 ↗
18. 10.1016/j.colsurfb.2015.07.04610.1016/j.colsurfb.2015.07.046 ↗
19. 10.1080/21691401.2016.117813110.1080/21691401.2016.1178131 ↗
20. 10.1080/21691401.2017.134788010.1080/21691401.2017.1347880 ↗
21. Ramazani A, Keramati M, Malvandi H, et al. Preparation and in vivo evaluation of anti-plasmodial properties of artemisinin-loaded PCL-PEG-PCL nanoparticles. Pharm Dev Technol. 2017;1–10.
22. 10.1016/j.msec.2015.11.06710.1016/j.msec.2015.11.067 ↗
23. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
24. 10.1208/s12249-015-0311-310.1208/s12249-015-0311-3 ↗
25. 10.1016/j.ijbiomac.2017.03.13710.1016/j.ijbiomac.2017.03.137 ↗
26. 10.1016/j.jcis.2014.06.03510.1016/j.jcis.2014.06.035 ↗
27. 10.1016/j.colsurfb.2015.04.01310.1016/j.colsurfb.2015.04.013 ↗
28. 10.3109/02652048.2015.111404210.3109/02652048.2015.1114042 ↗
29. 10.1007/s12272-016-0738-410.1007/s12272-016-0738-4 ↗
30. 10.1016/j.ijpharm.2015.09.02010.1016/j.ijpharm.2015.09.020 ↗
31. 10.1186/s11671-017-2169-710.1186/s11671-017-2169-7 ↗
32. 10.15171/apb.2015.04310.15171/apb.2015.043 ↗
33. 10.2147/IJN.S13383210.2147/IJN.S133832 ↗
34. 10.1016/j.colsurfb.2013.12.01910.1016/j.colsurfb.2013.12.019 ↗
35. 10.1039/C5CC00927H10.1039/C5CC00927H ↗
36. 10.2147/IJN.S10654810.2147/IJN.S106548 ↗
37. Leto I, Coronnello M, Righeschi C, et al. Enhanced efficacy of artemisinin loaded in transferrin-conjugated liposomes versus stealth liposomes against HCT-8 colon cancer cells. Chem Med. 2016;11:1745–1751.
38. 10.1038/aps.2017.1010.1038/aps.2017.10 ↗
39. 10.1016/j.ejbas.2017.02.00110.1016/j.ejbas.2017.02.001 ↗
40. 10.1016/j.nano.2015.09.00410.1016/j.nano.2015.09.004 ↗
41. 10.1016/j.ijpharm.2014.03.03610.1016/j.ijpharm.2014.03.036 ↗
42. 10.1016/j.nano.2015.11.01710.1016/j.nano.2015.11.017 ↗
43. 10.3109/10717544.2014.90588310.3109/10717544.2014.905883 ↗
44. 10.1016/j.ijpharm.2016.09.00810.1016/j.ijpharm.2016.09.008 ↗
45. 10.5935/0100-4042.2014008610.5935/0100-4042.20140086 ↗
46. 10.1590/S1984-8250201300040000210.1590/S1984-82502013000400002 ↗
47. 10.1039/c1nr10783f10.1039/c1nr10783f ↗
48. 10.3109/1061186X.2015.101643710.3109/1061186X.2015.1016437 ↗
49. 10.1016/j.biomaterials.2014.10.03110.1016/j.biomaterials.2014.10.031 ↗
50. 10.1016/j.biomaterials.2015.05.03610.1016/j.biomaterials.2015.05.036 ↗
51. 10.2147/IJN.S3032010.2147/IJN.S30320 ↗
52. 10.1016/j.partic.2016.06.00110.1016/j.partic.2016.06.001 ↗
53. 10.1016/j.biomaterials.2014.04.02810.1016/j.biomaterials.2014.04.028 ↗
54. 10.1039/C5NR02402A10.1039/C5NR02402A ↗
55. 10.18632/oncotarget.1763910.18632/oncotarget.17639 ↗
56. 10.1016/j.ijpharm.2016.09.00810.1016/j.ijpharm.2016.09.008 ↗